As Hormone Use Increases, Some Doctors Warn Slight Cancer Risk Is Being Overlooked

Yahoo Health reported that recent studies linking hormone therapy to breast cancer were deemed flawed, and that this assessment has made doctors reluctant to prescribe hormone therapy for menopause relief, despite growing interest in its benefits. The outlet highlighted that clinicians are weighing the uncertain risk profile against quality‑of‑life improvements for patients.

At the Onco‑Menopause conference, organizer Muna Al‑Khaifi underscored the need for tailored menopause management for cancer survivors, while MedPage Today covered hormone therapy and cancer risk alongside unrelated oncology issues such as pay cuts and post‑double mastectomy mammograms. An opinion piece in the Washington Post described a landmark study as flawed and recounted a personal impact, and The New York Times noted that hormone use is rising and some doctors warn that a slight cancer risk may be overlooked.

Together, the pieces illustrate a spectrum of concerns, from clinical hesitancy to survivorship care and financial pressures within oncology. Coverage does not specify the exact magnitude of the alleged slight risk, only that it may be missed under current monitoring practices.